B. Riley Has Negative Outlook of ATNM FY2025 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Equities researchers at B. Riley dropped their FY2025 earnings estimates for Actinium Pharmaceuticals in a note issued to investors on Tuesday, April 1st. B. Riley analyst Y. Zhi now anticipates that the company will earn ($0.95) per share for the year, down from their previous estimate of $0.16. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share.

Several other equities research analysts also recently weighed in on the company. StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Actinium Pharmaceuticals Price Performance

Actinium Pharmaceuticals stock opened at $1.52 on Thursday. Actinium Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $10.24. The company’s 50-day moving average is $1.27 and its 200 day moving average is $1.44. The firm has a market capitalization of $47.42 million, a P/E ratio of -1.09 and a beta of 0.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. Vontobel Holding Ltd. purchased a new stake in shares of Actinium Pharmaceuticals in the 4th quarter worth $32,000. Sei Investments Co. bought a new stake in shares of Actinium Pharmaceuticals in the fourth quarter valued at about $62,000. Barclays PLC lifted its stake in Actinium Pharmaceuticals by 323.0% in the third quarter. Barclays PLC now owns 42,935 shares of the company’s stock worth $81,000 after acquiring an additional 32,784 shares during the period. Bank of America Corp DE grew its holdings in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after acquiring an additional 34,176 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Actinium Pharmaceuticals during the 3rd quarter valued at about $112,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).